Latest On CEL-SCI Corporation (CVM):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 22:52 EST | News | CEL-SCI spikes after data presentation on lead asset Multikine | N/A |  |
| 2023-05-12 22:34 EST | News | Cel-Sci GAAP EPS of -$0.19 misses by $0.02 | N/A | |
| 2023-04-28 05:58 EST | News | CEL-SCI down 6% on $1.35M public offering | N/A | |
| 2023-04-19 21:54 EST | News | CEL-SCI climbs 14% on plans to seek conditional approval for Multikine in Canada | N/A | |
| 2023-03-21 18:56 EST | News | Cel-Sci: Stuck On Its First Next Step | N/A | |
About CEL-SCI Corporation (CVM):
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agre read more...ement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
General
- Name CEL-SCI Corporation
- Symbol CVM
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:25
- Last Split Date2017-06-15
- Fiscal Year EndSeptember
- IPO Date1987-01-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://cel-sci.com
Valuation
- Price/Book (Most Recent Quarter) 24.95
Financials
- Most Recent Quarter 2020-12-31
- Operating Margin -5899%
- Return on Assets -49%
- Return on Equity -183%
- Revenue 523158
- Earnings Per Share -$1.12
- Revenue Per Share $0.01
- Gross Profit -17281626
- Quarterly Earnings Growth -62.7%
Highlights
- Market Capitalization 747.36 million
- EBITDA -17405436
- PE Ratio -1.95
- Analyst Target Price $19
- Book Value Per Share $0.73
Share Statistics
- Shares Outstanding 40.53 million
- Shares Float 38.74 million
- % Held by Insiders 420%
- % Held by Institutions 30.86%
- Shares Short 7.58 million
- Shares Short Prior Month 7.93 million
- Short Ratio 3.98
- Short % of Float 19%
- Short % of Shares Outstanding 19%
Technicals
- Beta 2.04
- 52 Week High $27.89
- 52 Week Low $9.66
- 50 Day Moving Average 20.51
- 200 Day Moving Average 15.15
Dividends
- Dividend Date 2017-06-15
- ExDividend Date 1996-08-28
- Dividend Yield 0%
CEL-SCI Corporation (CVM) Dividend Calendar:
CVM's last dividend payment was made to shareholders on June 15, 2017.
CEL-SCI Corporation (CVM) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
CEL-SCI Corporation (CVM) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
CEL-SCI Corporation (CVM) Chart:
CEL-SCI Corporation (CVM) News:
Below you will find a list of latest news for CEL-SCI Corporation (CVM) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
CEL-SCI Corporation (CVM) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CVM Trades:
CEL-SCI Corporation (CVM) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-30 | 8-K (Current report) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-11 | 10-Q/A (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-10 | EFFECT (Notice of Effectiveness) | |
| 2020-07-08 | UPLOAD (SEC-generated letter) | |
| 2020-07-08 | CORRESP (Correspondence) | |
| 2020-07-02 | S-1 (General form for registration of securities under the Securities Act of 1933) | |
| 2020-07-02 | S-1 (General form for registration of securities under the Securities Act of 1933) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 8-K (Current report) | |
| 2020-05-26 | 8-K (Current report) | |
| 2020-05-26 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
CEL-SCI Corporation (CVM) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of CEL-SCI Corporation (CVM). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 420%
Institutional Ownership: 3086%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-04 | PETER R YOUNG | Director | Buy | 1,000.00 | 11.39 | 11,390.00 | 23,014.00 | |
| 2020-11-04 | PETER R YOUNG | Director | Buy | 2,000.00 | 11.34 | 22,670.00 | 25,014.00 | |
| 2020-09-30 | GEERT R KERSTEN | Chief Executive Officer | Buy | 335.00 | 12.75 | 4,271.25 | 1,120,146.00 | |
| 2020-09-30 | DANIEL H ZIMMERMAN | Senior Vice President | Buy | 275.00 | 12.75 | 3,506.25 | 115,186.00 | |
| 2020-09-30 | EYAL TALOR | Chief Scientific Officer | Buy | 188.00 | 12.75 | 2,397.00 | 119,043.00 | |
| 2020-09-30 | PATRICIA B PRICHEP | Senior Vice President | Buy | 297.00 | 12.75 | 3,786.75 | 206,134.00 | |
| 2020-06-30 | GEERT R KERSTEN | CEO | Buy | 286.00 | 14.92 | 4,267.12 | 1,119,811.00 | |
| 2020-06-30 | DANIEL H ZIMMERMAN | Senior VP, Research | Buy | 228.00 | 14.92 | 3,401.76 | 114,911.00 | |
| 2020-06-30 | EYAL TALOR | Chief Scientific Officer | Buy | 160.00 | 14.92 | 2,387.20 | 118,855.00 | |
| 2020-06-30 | PATRICIA B PRICHEP | Senior VP, Operations | Buy | 245.00 | 14.92 | 3,655.40 | 205,837.00 | |
| 2020-03-31 | GEERT R KERSTEN | Chief Executive Officer | Buy | 370.00 | 11.54 | 4,269.80 | 1,119,525.00 | |
| 2020-03-31 | DANIEL H ZIMMERMAN | Senior Vice President | Buy | 296.00 | 11.54 | 3,415.84 | 114,683.00 | |
| 2020-03-31 | EYAL TALOR | Chief Scientific Officer | Buy | 207.00 | 11.54 | 2,388.78 | 118,695.00 | |
| 2020-03-31 | PATRICIA B PRICHEP | Senior Vice President | Buy | 317.00 | 11.54 | 3,658.18 | 205,592.00 | |
| 2020-02-26 | GEERT R KERSTEN | Chief Executive Officer | Buy | 4,617.00 | 10.83 | 50,002.11 | 1,119,155.00 | |
| 2020-02-26 | DANIEL H ZIMMERMAN | Senior Vice President | Buy | 923.00 | 10.83 | 9,996.09 | 114,387.00 | |
| 2020-02-26 | PATRICIA B PRICHEP | Senior Vice President | Buy | 1,847.00 | 10.83 | 20,003.01 | 205,275.00 | |
| 2020-02-26 | PETER R YOUNG | Director | Buy | 923.00 | 10.83 | 9,996.09 | 22,014.00 | |
| 2020-02-26 | Robert Eugene Watson | Director | Buy | 923.00 | 10.83 | 9,996.09 | 2,381.00 | |
| 2020-02-26 | BRUNO JEAN-MARIE BAILLAVOINE | Director | Buy | 923.00 | 10.83 | 9,996.09 | 3,923.00 | |